Quantum BioPharma receives FDA clearance for Lucid-MS Phase 2 trials

Quantum BioPharma Ltd. has received FDA clearance to advance its lead multiple sclerosis candidate, Lucid-MS (Lucid-21-302), into Phase 2 clinical development. The Investigational New Drug application approval allows the company to begin patient enrollment and dosing for a disease-modifying trial aimed at halting demyelination.

Unlike existing therapies that modulate the immune system, Lucid-MS is designed to target neurodegeneration directly. The company is currently working with a clinical research organization to support the trial and is in the process of site selection.